JP5945096B2 - 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用 - Google Patents

抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用 Download PDF

Info

Publication number
JP5945096B2
JP5945096B2 JP2010542454A JP2010542454A JP5945096B2 JP 5945096 B2 JP5945096 B2 JP 5945096B2 JP 2010542454 A JP2010542454 A JP 2010542454A JP 2010542454 A JP2010542454 A JP 2010542454A JP 5945096 B2 JP5945096 B2 JP 5945096B2
Authority
JP
Japan
Prior art keywords
cancer
antibody
human
administration
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010542454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526674A (ja
JP2011526674A5 (OSRAM
Inventor
史朗 柴山
史朗 柴山
隆雄 吉田
隆雄 吉田
多門 林
多門 林
林　昭夫
昭夫 林
村井　淳
淳 村井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Priority to JP2010542454A priority Critical patent/JP5945096B2/ja
Publication of JP2011526674A publication Critical patent/JP2011526674A/ja
Publication of JP2011526674A5 publication Critical patent/JP2011526674A5/ja
Application granted granted Critical
Publication of JP5945096B2 publication Critical patent/JP5945096B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2010542454A 2008-07-04 2009-07-03 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用 Expired - Fee Related JP5945096B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010542454A JP5945096B2 (ja) 2008-07-04 2009-07-03 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2008176110 2008-07-04
JP2008176110 2008-07-04
JP2010542454A JP5945096B2 (ja) 2008-07-04 2009-07-03 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
PCT/JP2009/003093 WO2010001617A1 (en) 2008-07-04 2009-07-03 Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014223954A Division JP2015061844A (ja) 2008-07-04 2014-11-04 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用

Publications (3)

Publication Number Publication Date
JP2011526674A JP2011526674A (ja) 2011-10-13
JP2011526674A5 JP2011526674A5 (OSRAM) 2012-08-16
JP5945096B2 true JP5945096B2 (ja) 2016-07-05

Family

ID=41465723

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010542454A Expired - Fee Related JP5945096B2 (ja) 2008-07-04 2009-07-03 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
JP2014223954A Withdrawn JP2015061844A (ja) 2008-07-04 2014-11-04 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014223954A Withdrawn JP2015061844A (ja) 2008-07-04 2014-11-04 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用

Country Status (4)

Country Link
US (1) US8460886B2 (OSRAM)
EP (1) EP2307050A4 (OSRAM)
JP (2) JP5945096B2 (OSRAM)
WO (1) WO2010001617A1 (OSRAM)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA023913B1 (ru) 2009-05-11 2016-07-29 БЕРГ ФАРМА ЭлЭлСи Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
PL2435825T3 (pl) 2009-05-27 2015-12-31 Biotempus Ltd Sposoby leczenia chorób
SG188527A1 (en) * 2010-09-21 2013-04-30 Proteomics Internat Pty Ltd Biomarkers associated with pre-diabetes, diabetes and diabetes related conditions
MX341076B (es) * 2011-03-31 2016-08-04 Merck Sharp & Dohme Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
CN103608323B (zh) 2011-04-04 2016-08-17 博格有限责任公司 治疗中枢神经系统肿瘤的方法
ES2616289T3 (es) * 2012-03-01 2017-06-12 Miltenyi Biotec Gmbh Separación de neuronas vivas intactas
WO2013169693A1 (en) * 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
US20150177250A1 (en) * 2012-06-18 2015-06-25 Mayo Foundation For Medical Education And Research Determination of efficient time(s) for chemotherapy delivery
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
EP2983654B1 (en) 2013-04-08 2025-11-12 BPGbio, Inc. Treatment of cancer using coenzyme q10 combination therapies
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
WO2015035094A1 (en) 2013-09-04 2015-03-12 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
CA2935423C (en) * 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
AU2015210750B2 (en) 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
EP3114144A1 (en) * 2014-03-05 2017-01-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
WO2016057898A1 (en) 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
EP3943101A1 (en) 2014-10-21 2022-01-26 SciClone Pharmaceuticals International Ltd. Treatment of cancer with immune stimulator alpha thymosin peptide
AU2015339306B2 (en) 2014-10-29 2021-07-22 Bristol-Myers Squibb Company Combination therapy for cancer
JP2016148623A (ja) * 2015-02-13 2016-08-18 京都府公立大学法人 大腸がんの検出方法
BR112017020952A2 (pt) 2015-04-13 2018-07-10 Five Prime Therapeutics Inc método de tratamento de câncer, composição e uso da composição
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
AU2016298227B9 (en) 2015-07-30 2019-10-31 Macrogenics, Inc. PD-1-binding molecules and methods of use thereof
US10996217B2 (en) * 2015-08-06 2021-05-04 Sekisui Medical Co., Ltd. Method for examining renal disease
MX392711B (es) * 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
US20170189350A1 (en) 2015-11-16 2017-07-06 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
BR112018068461A2 (pt) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
US20180021270A1 (en) * 2016-07-21 2018-01-25 Berg Llc Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators
JP2019525934A (ja) * 2016-07-29 2019-09-12 イーライ リリー アンド カンパニー 癌の治療に使用するためのメレスチニブおよび抗ｐｄ−ｌ１または抗ｐｄ−１阻害剤を用いた組み合わせ治療
EP3666794A1 (en) 2016-11-01 2020-06-17 AnaptysBio, Inc. Antibodies directed against programmed death- 1 (pd-1)
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
EP3565844B8 (en) 2017-01-09 2023-04-12 Tesaro, Inc. Methods of treating cancer with anti-pd-1 antibodies
WO2018160538A1 (en) 2017-02-28 2018-09-07 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
WO2018204303A1 (en) 2017-05-01 2018-11-08 The Children's Medical Center Coporation Methods and compositions relating to anti-pd1 antibody reagents
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3066053A1 (en) 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
US12070489B2 (en) 2018-12-12 2024-08-27 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with a cancer therapy in combination with another therapeutic agent
US12016900B2 (en) 2017-06-04 2024-06-25 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
CA3073531A1 (en) 2017-09-13 2019-03-21 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
EP3681528B1 (en) * 2017-09-13 2025-07-23 Mayo Foundation for Medical Education and Research Identification and monitoring of apoptosis inhibitor of macrophage
EP3717021A1 (en) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
JP2021506883A (ja) 2017-12-21 2021-02-22 メルサナ セラピューティクス インコーポレイテッド ピロロベンゾジアゼピン抗体結合体
AU2019288276B2 (en) 2018-06-20 2026-02-12 Incyte Corporation Anti-PD-1 antibodies and uses thereof
CN113056482A (zh) 2018-10-18 2021-06-29 默沙东公司 抗rsv抗体的制剂及其使用方法
MX2021004906A (es) 2018-10-29 2021-09-10 Mersana Therapeutics Inc Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos.
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
US20220107320A1 (en) 2019-02-15 2022-04-07 Incelldx, Inc. Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
WO2020227431A1 (en) 2019-05-06 2020-11-12 Brown University Bispecific antibodies against chi3l1 and pd1 with enhanced t cell-mediated cytotoxic effects on tumor cells
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
WO2023017525A1 (en) 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
WO2023236099A1 (en) * 2022-06-08 2023-12-14 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against enpp3 and uses thereof
CN120476314A (zh) * 2023-01-10 2025-08-12 宫崎彻 癌症的诊断方法
WO2025034883A1 (en) 2023-08-08 2025-02-13 Quanta Therapeutics, Inc. Combination therapies with kras modulators
WO2025106905A1 (en) 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Combination therapies with a kras modulator and an immunomodulator inhibitor
WO2026060384A1 (en) 2024-09-16 2026-03-19 Quanta Therapeutics, Inc. Combination therapies with kras modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07291996A (ja) 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
PT1537878E (pt) * 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
PL2161336T5 (pl) * 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
US20100004871A1 (en) * 2005-12-27 2010-01-07 Power3 Medical Products, Inc. Identities, specificities, and use of twenty two (22) differentially expressed protein biomarkers for blood based diagnosis of breast cancer

Also Published As

Publication number Publication date
US8460886B2 (en) 2013-06-11
JP2015061844A (ja) 2015-04-02
EP2307050A4 (en) 2012-07-25
EP2307050A1 (en) 2011-04-13
JP2011526674A (ja) 2011-10-13
US20110123550A1 (en) 2011-05-26
WO2010001617A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
JP2015061844A (ja) 抗ヒトｐｄ−１抗体の癌に対する治療効果を最適化するための判定マーカーの使用
US10968273B2 (en) Antibody recognizing human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US8008009B2 (en) Method for ProNGF assay for in vitro diagnosis of cancer in particular breast, thyroid or lung cancer and therapeutic use of ProNGF
BR112012032008B1 (pt) Anticorpos s100a4, linhagem celular de hibridoma, composição farmacêutica, conjugado, método e kit para diagnosticar câncer ou uma doença associada à inflamação
US20230075633A1 (en) Optimized anti-cd3 arm in the generation of t-cell bispecific antibodies for immunotherapy
CN101553728B (zh) 颗粒体蛋白-上皮素前体(gep)抗体用于检测和抑制肝细胞癌(hcc)的用途
EP2984108A1 (en) Anti-s100a7 antibodies for the treatment and diagnosis of cancer
US9850303B2 (en) Hybridoma clones and monoclonal antibodies to tetraspanin 8
Kim et al. Targeting metastatic breast cancer with peptide epitopes derived from autocatalytic loop of Prss14/ST14 membrane serine protease and with monoclonal antibodies
US20160032002A1 (en) Hybridoma Clones and Monoclonal Antibodies to CD9
US20080199470A1 (en) The Use of Granulin-Epithelin Precursor (GEP) Anitbodies for Detection and Suppression of Hepatocellular Carcinoma (HCC)
US9206258B2 (en) Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same
Taher et al. Immunohistochemical Expression of CD34 as Biological Marker of Angiogenesis and Expression of D2-40 as Marker of Lymphangiogenesis in Mucoepidermoid Carcinoma of Salivary Glands.
CN105474016B (zh) Augurin免疫试验
EP4729544A1 (en) Use of claudin-3 as target for diagnosis and treatment of small cell lung cancer
ES3053649T3 (en) Antibody specifically binding to pauf protein and use thereof
EP4683930A1 (en) C3f assay
WO2020101039A1 (ja) 血中ケモカインを用いた免疫チェックポイント阻害薬の治療効果判定
HK1220763B (zh) Augurin免疫试验
JP2014185101A (ja) 細胞の転移又は浸潤抑制剤
HK40003673A (en) Monoclonal antibody and application thereof
HK1180702B (en) Antibody recognising human leukemia inhibitory factor (lif) and use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131031

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131108

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140110

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20140411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141104

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20141201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150202

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150224

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160328

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160527

R150 Certificate of patent or registration of utility model

Ref document number: 5945096

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees